论文部分内容阅读
目的对促肝细胞生长素治疗重型肝炎的临床效果进行研究。方法 60例重型肝炎患者,将患者简单随机分为对照组和观察组,每组30例。对照组患者接受常规治疗,观察组患者在对照组治疗基础上给予促肝细胞生长素治疗,对两组患者肝功能指标变化情况、不良反应及死亡情况进行比较。结果观察组患者治疗后的凝血酶原活动度(PTA)、血清前白蛋白(PA)均明显较治疗前升高,总胆红素(TBIL)、丙氨酸转氨酶(ALT)明显较治疗前下降,且观察组改善程度均明显优于对照组(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05);观察组死亡率(6.67%)明显低于对照组(30.00%),差异具有统计学意义(P<0.05)。结论促肝细胞生长素在重型肝炎治疗中的疗效可观,可在临床广泛应用。
Objective To study the clinical effect of hepatocyte growth-promoting hormone in the treatment of severe hepatitis. Methods Sixty patients with severe hepatitis were randomly divided into control group and observation group with 30 cases in each group. Patients in the control group received conventional therapy. Patients in the observation group were given hepatocyte growth-promoting hormone (HGF) on the basis of the control group. The changes of liver function indexes, adverse reactions and death were compared between the two groups. Results After treatment, the activity of prothrombin (PTA) and pre-serum albumin (PA) in the observation group were significantly higher than those before treatment, and the total bilirubin (TBIL) and alanine aminotransferase (ALT) Decreased, and the observation group were significantly better than the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). The mortality rate in the observation group (6.67%) was significantly lower than that in the control group (30.00%). The difference was statistically significant (P <0.05). Conclusions Hepatocyte growth-promoting hormone has a good curative effect in the treatment of severe hepatitis, which can be widely used in clinical practice.